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1523Transcatheter aortic valve replacement (TAVR) improves
mortality compared with standard therapy among inoperable
patients with severe, symptomatic aortic stenosis (1) and
demonstrates similar outcomes as surgical aortic valve
replacement (SAVR) among patients at high surgical risk (2).
Notably, unlike trials in most other cardiovascular disease
states, female patients represent a signiﬁcant proportion of
enrolled patients in TAVR studies. Prior analyses have
demonstrated differences between males and females in pre-
existing comorbidities as well as the left ventricular response
to severe aortic stenosis, potentially explaining improved
clinical outcomes for female patients (3–5). The impact of sex
on long-term outcomes after SAVR is less certain, as are sex-
speciﬁc differences after either TAVR or SAVR. Given the
importance of identifying subgroups that beneﬁt preferen-
tially from TAVR, we examined the sex-related characteris-
tics and outcomes of high-risk patients undergoing TAVR
versus SAVR in the PARTNER (Placement of Aortic
Transcatheter Valve) trial.
Methods
The PARTNER trial randomly allocated 699 high-risk
patients with severe aortic stenosis to TAVR (Edwards
SAPIEN valve, Edwards Lifesciences, Irvine, California) or
SAVR (Carpentier Edwards pericardial prosthesis), as pre-
viously described (2). Randomization was stratiﬁed by
transapical or transfemoral vascular access. Clinical and
echocardiographic follow-up was obtained for 2 years;
events were adjudicated independently using standardized
endpoint deﬁnitions (6) and reported by intention-to-treat
analysis; echocardiograms were analyzed at an independent
core laboratory and analyzed “as treated” (7,8). Categorical
variables were compared using Fisher’s exact test, and
continuous variables were compared using Student t test.
Event rates for procedural outcomes are reported as Kaplan-
Meier estimates. Survival curves for time-to-event variables
used Kaplan-Meier estimates and were compared using the
log-rank test. Cox proportional hazards models were used
to calculate hazard ratios (HRs) and to test for interactions
between sex and treatment approach. Data were extracted
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Population. Of the subjects,
42.9% were female, including
42.2% TAVR and 43.6% SAVR.
Among transfemoral patients,
39.3% were female compared
with 49% in the transapical arm.
Baseline characteristics differed signiﬁcantly between males
and females (Table 1) but not between patients assigned to
TAVR versus SAVR. Baseline echocardiographic variables
also differed signiﬁcantly between sexes (Table 2). Although
transvalvular gradients were higher in females, there were no
differences in valve area after indexing to body size (0.36
cm2/m2 vs. 0.35 cm2/m2; p ¼ 0.55). Annular diameters were
smaller in females (1.92 cm vs. 2.07 cm; p < 0.0001), and
thus 80% of females received a 23-mm valve (vs. 25.3% of
males; p < 0.0001).
Procedural (30-day or in-hospital) outcomes. Among
females, procedural mortality trended lower with TAVR
compared with SAVR (6.8% vs. 13.1%; p ¼ 0.07) (Table 3),
although procedural stroke rates were higher (5.4% vs. 0.7%;
p ¼ 0.02) because of differences in the transfemoral arm
(Fig. 1). Vascular complications were more common with
TAVR (15% vs. 4.6%; p < 0.01) whereas bleeding was
more frequentwithSAVR(10.9% vs. 21.6%; p¼ 0.01).TAVR
echocardiographic valve areas were larger (1.49 cm2 vs. 1.36
cm2; p¼ 0.01), and only 3% had moderate-severe paravalvular
leak, but there were no differences between TAVR and SAVR
in peak gradients (22.72 mmHg vs. 25 mm Hg; p ¼ 0.06) or
mean gradients (11.86 mmHg vs. 12.91 mmHg; p ¼ 0.08).
Similar to females, procedural mortality among males
was lower with TAVR compared with SAVR (6% vs.
12.1%; p ¼ 0.03), but there was no difference in stroke rates
(4% vs. 4%; p ¼ 0.98) (Table 3, Fig. 1). Vascular compli-
cations were more frequent with TAVR (8% vs. 2.5%;
p ¼ 0.02) whereas bleeding was more common with SAVR
(9.5% vs. 21.2%; p ¼ 0.001). Also similar to females, TAVR
echocardiographic valve areas were larger (1.71 cm2 vs.
1.55 cm2; p < 0.01), but there were no differences in peak
transaortic gradients (19.60 mm Hg vs. 22.04 mm Hg;
p ¼ 0.08) or mean transaortic gradients (10.13 mm Hg vs.
11.13 mm Hg; p ¼ 0.17). Moderate-severe paravalvular leak
was present in 10.3% of male TAVR patients (Table 4).
Two-year outcomes. Among females, all-cause mortality
was signiﬁcantly lower with TAVR compared with SAVR at
6 months (12.2% vs. 25.8%; p < 0.01) and 2-year follow-up
(28.2% vs. 38.2%; HR: 0.67; 95% conﬁdence interval [CI]:
0.44 to 1.00; p ¼ 0.049) (Fig. 2A). Although there was no
interaction between access site (transfemoral vs. transapical)
and treatment group (p ¼ 0.13), differences in late mortality
were driven by the transfemoral cohort (23.4% vs. 36.9%;
HR: 0.55; 95% CI: 0.32 to 0.93; p ¼ 0.02), with no mor-
tality difference in the transapical cohort (Fig. 3A and B).
Among males, mortality in TAVR and SAVR was
similar at 6 months (15% vs. 19.8%; p ¼ 0.17) and at 2 years
Table 1 Baseline Demographics
Characteristic
Female Male
p Value for
InteractionTAVR SAVR p Value TAVR SAVR p Value
Age, yrs 84.5  6.34 85.3  5.70 0.31 82.9  7.11 83.9  6.79 0.17 0.81
STS score 11.85  2.77 12.01  3.37 0.66 11.79  3.70 11.44  3.53 0.3 0.34
Logistic EuroSCORE 27.52  15.70 26.82  13.48 0.9 30.69  16.93 31.10  16.92 0.72 0.66
NYHA functional class
I 0.0 0.0 NA 0.0 0.0 NA NA
II 6.1 6.6 0.86 5.5 5.6 0.97 0.92
III 40.8 44.4 0.54 42.3 42.4 0.98 0.65
IV 53.1 49.0 0.48 52.2 52 0.97 0.62
CAD 62.6 66.2 0.51 83.6 83.8 0.94 0.7
Previous MI 18.4 20.7 0.62 32.5 36.7 0.38 0.91
Prior PCI 27.2 27.3 0.98 38.2 34.8 0.49 0.65
Prior CABG 19.0 20.5 0.75 59.7 61.1 0.77 0.92
CVD 28.3 25.5 0.61 30.2 27.7 0.59 0.96
PVD 35.9 36.9 0.85 48.5 45.3 0.53 0.58
Diabetes mellitus 34.7 36.4 0.76 47.8 43.4 0.39 0.43
BSA, m2 1.69  0.23 1.69  0.21 0.88 1.93  0.21 1.92  0.19 0.46 0.68
Smoking 34.0 32.5 0.77 60.7 60.6 0.99 0.84
COPD
Any 22.5 19.8 0.66 15.0 14.9 0.98 0.76
Oxygen dependent 10.9 7.9 0.38 8.0 6.6 0.59 0.8
Creatinine >2 mg/dl 10.2 13.2 0.41 24.5 23.2 0.77 0.4
Major arrhythmia 45.6 48.7 0.59 47.3 54 0.18 0.63
Permanent pacemaker 14.3 10.6 0.33 23.9 30.3 0.15 0.11
Pulmonary hypertension 56.5 49.7 0.24 45.8 46.5 0.89 0.33
Liver disease 0.7 4.0 0.12 3.5 2.5 0.58 0.09
Values are mean  SD or %.
BSA ¼ body surface area; CABG ¼ coronary artery bypass graft surgery; CAD ¼ coronary artery disease; COPD ¼ chronic obstructive pulmonary disease; CVD ¼ cerebrovascular disease;
EuroSCORE ¼ European System for Cardiac Operative Risk Evaluation; MI ¼ myocardial infarction; NA ¼ not applicable; NYHA ¼ New York Heart Association; PCI ¼ percutaneous coronary intervention;
PVD ¼ peripheral vascular disease; SAVR ¼ surgical aortic valve replacement; STS ¼ The Society of Thoracic Surgeons; TAVR ¼ transcatheter aortic valve replacement.
Table 2 Baseline Echocardiographic Findings
Female Male
p Value for
InteractionTAVR SAVR p Value TAVR SAVR p Value
Peak gradient, mm Hg 75.4  25.3 80.1  27.2 0.18 68.5  22.4 68.4  20.4 0.80 0.19
Mean gradient, mm Hg 45.6  15.7 47.6  16.1 0.31 40.9  13.5 40.4  12.1 0.90 0.26
AVA, cm2 0.63  0.20 0.58  0.19 0.02 0.67  0.20 0.67  0.19 0.74 0.20
AVAi, cm2/m2 0.38  0.12 0.33  0.10 0.008 0.36  0.11 0.36  0.13 0.99 0.44
Aortic annulus, cm 1.93  0.20 1.89  0.19 0.59 2.06  0.26 2.07  0.22 0.57 0.26
Ejection fraction, % 55.2  18.6 55.7  13.7 0.79 49.6  14.4 51.9  12.2 0.33 0.51
Stroke volume, ml 53.5  18.6 51.2  17.5 0.35 67.0  24.0 67.1  19.6 0.54 0.56
Cardiac output, l/min 3.58  1.22 3.57  1.31 0.64 4.51  1.58 4.46  1.66 0.61 0.90
Cardiac index, l/min/m2 2.07  0.72 2.16  1.03 0.98 2.48  0.87 2.50  0.97 0.73 0.73
LVED volume, ml 100.9  36.1 96.8  38.0 0.41 142.1  50.5 135.5  45.3 0.38 0.78
LVES volume, ml 47.4  27.5 45.5  29.0 0.51 75.1  41.7 68.3  36.1 0.38 0.49
LVED dimension, cm 4.16  0.65 4.24  0.74 0.56 4.76  0.75 4.73  0.75 0.60 0.37
LVES dimension, cm 2.87  0.79 2.92  0.89 0.97 3.58  0.94 3.54  0.92 0.50 0.53
LV mass, g 246.9  78.5 254.6  86.5 0.65 306.0  79.2 294.4  82.6 0.18 0.16
Mitral regurgitation
None 2.9 2.9 1.00 4.2 2.6 0.39 0.61
Trace 25.5 16.4 0.06 24.9 26.2 0.77 0.10
Mild 48.2 55.7 0.21 54.5 52.4 0.68 0.22
Moderate 19.0 22.1 0.51 14.8 16.8 0.60 0.91
Severe 4.4 2.9 0.54 1.6 2.1 1.00 0.47
Values are mean  SD or %.
AVA ¼ aortic valve area; AVAi ¼ aortic valve area indexed; LV ¼ left ventricular; LVED ¼ left ventricular end diastolic; LVES ¼ left ventricular end systolic; other abbreviations as in Table 1.
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Table 3 Procedural Outcomes
Outcome
Female Male
p Value for
InteractionTAVR Surgery p Value TAVR Surgery p Value
All mortality 6.8 13.1 0.07 6.0 12.1 0.03 0.10
Cardiac mortality 4.8 3.9 0.72 3.5 6.1 0.23 0.04
Rehospitalization 6.8 6.5 0.93 4.0 2.0 0.25 0.22
Death or rehospitalization 13.6 18.3 0.27 9.0 13.6 0.14 0.21
All stroke or TIA 6.8 0.7 <0.01 4.5 4.0 0.98 0.07
TIA 1.4 0.0 0.24 0.5 0.5 1.00 0.99
All stroke 5.4 0.7 0.02 4.0 4.0 0.98 0.09
Death/major stroke 10.9 13.1 0.56 8.5 15.7 0.03 0.01
Vascular complications
All 23.8 5.2 <0.0001 13.9 3.0 <0.0001 0.87
Major 15.0 4.6 <0.01 8.0 2.5 0.02 0.87
Unplanned arterial procedure 18.4 3.9 <0.0001 9.5 2.0 0.001 0.91
Major bleeding 10.9 21.6 0.01 9.5 21.2 0.001 0.81
New pacemaker 4.8 6.5 0.51 4.0 1.0 0.11 0.06
MI 0.0 1.3 0.50 0.0 0.0 NA 0.99
Acute kidney injury* 3.4 6.5 0.21 5.0 3.5 0.48 0.16
Values are %. *Renal failure requiring dialysis.
TIA ¼ transient ischemic attack; other abbreviations as in Table 1.
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1525(37.7% vs. 32.3%; HR: 1.15; 95% CI: 0.82 to 1.61; p¼ 0.42)
(Fig. 2B), with no reduction in either arm (Figs. 3C and 3D).
Excluding procedural deaths, mortality was higher with
TAVR than SAVR (HR: 1.58; 95% CI: 1.06 to 2.36;
p ¼ 0.02).Discussion
Among male and female patients in the randomized
PARTNER trial evaluating TAVR versus SAVR we found
the following: 1) signiﬁcant differences in important co-
morbid conditions that may account for differences in late
mortality; 2) a survival beneﬁt for female, but not for male
patients, with TAVR compared with SAVR, especiallyFigure 1 Incidence of Procedural Stroke
Incidence of procedural stroke after either transcatheter aortic valve replacement (TAVR) (b
the transfemoral arm and in (B) the transapical arm.using a transfemoral approach; and 3) higher stroke risk for
female patients with TAVR but no differences among male
patients.
The impact of sex on outcomes after SAVR is unclear
although the STS risk model includes female sex as a sig-
niﬁcant risk factor for mortality (HR: 1.23) (9). Although
adjusted procedural outcomes do not differ by sex (10,11),
long-term survival is better among women undergoing
SAVR (12,13), particularly if a bioprosthesis is implanted
(13). Others have shown that despite no difference in sur-
vival, women respond differently to SAVR with a greater
improvement in ejection fraction after intervention (10).
Although the PARTNER trial demonstrated similar
mortality for SAVR and TAVR, outcomes differ accordinglue bars) or surgical aortic valve replacement (SAVR) (red bars) stratiﬁed by sex in (A)
Table 4 Echocardiographic Findings at Discharge
Female Male
p Value
(a) vs. (d)
p Value
(b) vs. (e)
(a) TAVR
(n ¼ 146)
(b) Surgery
(n ¼ 134) p Value
(d) TAVR
(n ¼ 201)
(e) Surgery
(n ¼ 198) p Value
Peak gradient 22.72  8.55 25.00  9.91 0.06 19.60  8.18 22.04  10.19 0.08 0.001 0.008
Mean gradient 11.86  4.84 12.91  5.45 0.08 10.13  4.30 11.13  5.13 0.17 0.002 0.004
AVA, cm2 1.49  0.42 1.36  0.42 0.01 1.71  0.55 1.55  0.48 0.009 <0.001 0.001
AVAi, cm2/m2 0.89  0.27 0.81  0.26 0.03 0.90  0.30 0.81  0.27 0.009 0.97 0.98
PVL
None 28.0 83.9 <0.0001 23.9 80.7 <0.0001 0.41 0.50
Trace 27.3 12.5 0.004 23.9 13.8 0.02 0.50 0.76
Mild 41.7 3.6 <0.0001 41.8 4.8 <0.0001 0.97 0.76
Moderate 3.0 0.0 0.13 9.2 0.7 0.0007 0.03 1.0
Severe 0.0 0.0 NA 1.1 0.0 0.51 0.51 NA
Ejection fraction 57.8  11.4 54.4  12.40 0.20 53.6  12.0 52.0  12.0 0.39 0.07 0.35
Values are mean  SD or %.
PVL ¼ paravalvular leak; other abbreviations as in Tables 1 and 2.
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1526to the patient’s sex (2). In the current study, a modest
difference in procedural mortality favoring TAVR in fe-
male patients continues to increase over time so that at
6 months and 2 years, SAVR mortality was signiﬁcantly
higher. Conversely, there was no mortality difference be-
tween TAVR and SAVR among men. Although maleFigure 2 All-Cause Mortality
Kaplan-Meier estimates for all-cause mortality after either transcatheter aortic
valve replacement (TAVR) (red lines) or surgical aortic valve replacement (SAVR)
(blue lines) in (A) female patients and (B) male patients.patients experienced lower procedural mortality with
TAVR versus SAVR, 2-year mortality actually tended to
be higher among men treated with TAVR as compared
with SAVR.
These differences in late outcomes may be driven by
differences in baseline characteristics. Women were less
likely to have important comorbidities including coronary
artery disease, peripheral vascular disease, diabetes mellitus,
and renal dysfunction. Once a female patient survives the
procedural period, the initial beneﬁt of lower mortality with
TAVR is sustained. Among male patients, however, the
early beneﬁt of lower procedural mortality with TAVR
appears to be overwhelmed by competing risks (baseline
factors as well as post-implant complications), leading to
higher mortality in follow-up.
Another interesting ﬁnding from this study is the sex-
related difference in outcomes in the transfemoral and
transapical arms of the trial. Among women, late mortality
was dramatically lower with TAVR as compared with SAVR
among patients who were suitable for transfemoral access
(23.4% vs. 36.9%; p¼ 0.02), whereas among patients without
suitable transfemoral access (in whom TAVR was performed
by a transapical approach), 2-year mortality was similar with
TAVR and SAVR (37.3% vs. 41.7%; p ¼ 0.62). For male
patients, however, there was no signiﬁcant difference in late
outcomes between TAVR and SAVR in either the trans-
femoral or transapical arm. It is important to note that the
study was not powered to detect mortality differences in each
access stratum. The transapical population had increased
rates of important comorbidities such as previous coronary
artery bypass grafting, cerebrovascular disease, and peripheral
vascular disease that may have inﬂuenced mortality.
Procedural complications also varied by sex. Unlike
prior reports (13,14), our study showed lower procedural
strokes among female subjects versus male subjects in the
SAVR group (0.7% vs. 4%; p ¼ 0.08), but similar to prior
reports (4), there was no difference in the TAVR group
(4.8% vs. 4%; p ¼ 0.73) despite having less vascular
Figure 3 All-Cause Mortality Stratiﬁed by Sex and Treatment Approach
Kaplan-Meier estimates for all-cause mortality after either transcatheter aortic valve replacement (TAVR) (red lines) or surgical aortic valve replacement (SAVR) (blue lines)
stratiﬁed by sex and treatment approach (transfemoral vs. transapical). A ¼ female-transfemoral arm; B ¼ female-transapical arm; C ¼ male-transfemoral arm; D ¼ Male-
transapical arm.
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1527disease, suggesting that embolic risk with TAVR is due to
liberation of debris from the aortic valve. Vascular com-
plications were also more frequent among female patients
in the TAVR group (23.8% vs. 13.9%; p ¼ 0.02), a
ﬁnding seen in some studies (4,15), but not all (3). Despite
more vascular and neurologic complications, the better
outcomes after TAVR for women offer further support
for the importance of other comorbidities as drivers of
late mortality in men. Smaller, next-generation devices with
lower vascular and bleeding complications may further
improve outcomes with TAVR over SAVR in women.
Echocardiographic outcomes differed, with moderate or
severe paravalvular aortic regurgitation being more frequent
in men versus women undergoing TAVR (10.3% vs. 3%;
p ¼ 0.03), perhaps because of more frequent undersizing of
valves. Because of the association of paravalvular aortic
regurgitation with increased mortality (16–20), that may
contribute to the lack of TAVR beneﬁt seen for men and may
be remedied by next-generation valves and better sizing
algorithms.Study limitations. As a retrospective subanalysis of the
PARTNER trial, the current study is not adequately pow-
ered to evaluate mortality outcomes. This study represents
an early experience with TAVR. With increased procedural
expertise and device iterations, outcomes will likely improve.
Finally, these results only apply to high-risk patients and
cannot be extrapolated to moderate-risk patients with aortic
stenosis.
Conclusions
Despite higher incidences of vascular complications and
strokes, women had better late mortality with TAVR than
with SAVR. That was especially true in the transfemoral
arm and suggests that for high-risk female patients, TAVR
is a better option than surgery. Because the study was not
powered for this subgroup analysis, the results should be
considered hypothesis generating and a randomized,
controlled trial in female subjects is necessary to properly
study differences in outcomes.
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